View printer-friendly version


EU Physicians to Present Experiences with CHEMOSAT as a New Treatment Option for Cancers in the Liver

NEW YORK, Sept. 10, 2012 -- Delcath Systems, Inc. (NASDAQ: DCTH) today announced that the Company will be hosting a satellite symposium at the annual meeting of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) in Lisbon, Portugal on Monday, Sept. 17.

The program-Hepatic Chemosaturation Therapy: Expanding the Therapeutic Approaches of Interventional Radiology-will feature an expert panel of European physicians experienced in the use of the Generation Two Delcath Hepatic CHEMOSAT® Delivery system in the treatment of cancers in the liver. Moderated by Barry T. Katzen, MD, FACR, FACC, FSIR at Baptist Cardiac and Vascular Institute, Miami, Florida, the program will include presentations by:

  • Franco Orsi, MD, PhD, European Institute of Oncology, Milan, Italy - Concentrated Therapy: Critical Importance of Disease Control in the Liver 

  • Thomas J. Vogl, MD, Johann Wolfgang Goethe-Universität, Frankfurt, Germany - Chemosaturation: Targeting Both Visualized and Occult Liver Tumours 

  • Pier Francesco Ferrucci, MD, European Institute of Oncology, Milan, Italy - The Pivotal Role of the IR in Patient Management: Oncologists' Perspective 

"This session is an opportunity for experienced physicians from our European early launch sites to present the clinical uses they see for CHEMOSAT in the treatment of cancers in the liver," said Eamonn P. Hobbs, President and CEO of Delcath. "The distinguished panel we've assembled includes physicians who've experience first-hand the benefits of the Generation 2 CHEMOSAT system. CHEMOSAT represents an opportunity for interventional radiologists to play a central role in the management of patients with liver dominant disease, and we are confident this program will be the subject of considerable interest at CIRSE."

About Delcath Systems

Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath announced that its randomized Phase III clinical trial for patients with metastatic melanoma in the liver had successfully achieved the study's primary endpoint of extended hepatic progression-free survival. The Company also completed a multi-arm Phase II trial to treat other liver cancers. The Company obtained authorization to affix a CE Mark for the Delcath Hepatic CHEMOSAT® delivery system in April 2011 and for the second generation hemofiltration cartridge for CHEMOSAT in April 2012. The right to affix the CE mark allows the Company to market and sell the CHEMOSAT system in Europe. The Company has not yet received FDA approval for commercial sale of its system in the United States. The Company filed a New Drug Application (NDA) for its proprietary chemosaturation system with the second-generation hemofiltration cartridge in August 2012 seeking FDA approval for commercial sale of its chemosaturation system with melphalan. For more information, please visit the Company's website at

Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to: acceptance of the Company's new drug application (NDA) including the Generation 2 filter, the FDA's granting of our request for priority review, the timing of a PDUFA date, acceptability of the Phase 1, 2 and 3 clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales, if any, in the United States, the benefits of the Generation 2 CHEMOSAT system and market acceptance of the same, patient outcomes using the Generation 2 system, the timing of the supply and distribution of the CHEMOSAT system to early launch centers in Europe, the time required to build inventory and establish commercial operations in Europe, adoption, use and resulting sales, if any, for the Hepatic CHEMOSAT delivery system in the EEA, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver, approval of the current or future chemosaturation system for other indications, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for the CHEMOSAT system, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, uncertainties relating to the results of research and development projects and future clinical trials, acceptance of our IND amendment, the timing and use, if any, of the line of credit from SVB, and our ability to access this facility, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

Contact Information:
Investor Contact: Media Contact:
Doug Sherk/Gregory Gin     Janine McCargo
EVC Group  EVC Group
415-568-4887/646-445-4801    646-688-0425